Eli Lilly Reports Strong Q3 Results Driven by Mounjaro and Jardiance Growth
Eli Lilly has reported robust third-quarter financial results, significantly exceeding analyst expectations for both revenue and earnings per share. The company's non-GAAP EPS reached $7.48, beating estimates by $0.87, while total revenue climbed to $24.4 billion, surpassing projections by $1.78 billion. The primary drivers of this growth are the company's blockbuster metabolic and diabetes treatments. Mounjaro has seen massive scale with sales reaching $10.7 billion, while Jardiance experienced a significant surge of 64.5%. This momentum in the weight-loss and diabetes sectors has prompted Eli Lilly to lift its overall sales outlook.
Topics: earnings beat pharmaceuticals revenue growth weight-loss drugs
Read the full article at Seeking Alpha
Part of the story Mobileye Raises Full-Year Revenue Outlook Amid Growth in ADAS and Chinese Vehicle Exports (7 articles)